These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7500552)

  • 1. [Restenosis after percutaneous transluminal coronary angioplasty in the elderly--risk factor analysis].
    Ishikawa Y; Fujioka Y; Kitagawa Y; Nobusawa A; Takahashi A; Taniguchi T; Yokoyama M
    Nihon Ronen Igakkai Zasshi; 1995 Jul; 32(7):491-6. PubMed ID: 7500552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restenosis after transluminal coronary angioplasty: a risk factor analysis.
    Gürlek A; Dağalp Z; Oral D; Omürlü K; Erol C; Akyol T; Tutar E
    J Cardiovasc Risk; 1995 Feb; 2(1):51-5. PubMed ID: 7606641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of an acute reduction in lipoprotein(a) with coronary artery restenosis after percutaneous transluminal coronary angioplasty.
    Horie H; Takahashi M; Izumi M; Takaoka A; Fujita T; Sakamoto T; Kito O; Okamura H; Kinoshita M
    Circulation; 1997 Jul; 96(1):166-73. PubMed ID: 9236431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of serum lipoprotein (a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty.
    Hearn JA; Donohue BC; Ba'albaki H; Douglas JS; King SB; Lembo NJ; Roubin GS; Sgoutas DS
    Am J Cardiol; 1992 Mar; 69(8):736-9. PubMed ID: 1532112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between serum lipoprotein(a) and restenosis after initial elective percutaneous transluminal coronary angioplasty.
    Tenda K; Saikawa T; Maeda T; Sato Y; Niwa H; Inoue T; Yonemochi H; Maruyama T; Shimoyama N; Aragaki S
    Jpn Circ J; 1993 Aug; 57(8):789-95. PubMed ID: 8355396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term and long-term effects of low-density lipoprotein (LDL) apheresis on restenosis after percutaneous transluminal coronary angioplasty (PTCA): is lowering Lp(a) by LDL apheresis effective on restenosis after PTCA?
    Kanemitsu S; Takekoshi N; Matsui S; Tsugawa H; Ohkubo S; Kitayama M; Matsuda T; Senma J; Masuyama K; Yamagata T; Murakami E
    Ther Apher; 1998 Feb; 2(1):65-70. PubMed ID: 10227791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinogen values in patients with and without restenosis following percutaneous transluminal coronary angiography.
    Schumacher M; Eber B; Tiran A; Toplak H; Luha O; Gasser R; Klein W
    Cardiology; 1992; 80(5-6):345-8. PubMed ID: 1451121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein(a) in restenosis after percutaneous transluminal coronary angioplasty and coronary artery disease.
    Cooke T; Sheahan R; Foley D; Reilly M; D'Arcy G; Jauch W; Gibney M; Gearty G; Crean P; Walsh M
    Circulation; 1994 Apr; 89(4):1593-8. PubMed ID: 8149526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty.
    Watanabe K; Sekiya M; Ikeda S; Miyagawa M; Hashida K
    Am Heart J; 1996 Jul; 132(1 Pt 1):23-9. PubMed ID: 8701872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum lipids and lipoproteins in relation to restenosis after coronary angioplasty.
    Johansson SR; Wiklund O; Karlsson T; Hjalmarson A; Emanuelsson H
    Eur Heart J; 1991 Sep; 12(9):1020-8. PubMed ID: 1936002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The importance of serum lipid level for restenosis following initial successful percutaneous transluminal coronary angioplasty in patients with unstable angina].
    Kishi K; Hiasa Y; Tanaka H; Tanimoto M; Kinoshita M; Shinohara A; Wada T; Aihara T
    J Cardiol; 1996 Aug; 28(2):79-84. PubMed ID: 8814525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum lipids and restenosis after successful percutaneous transluminal coronary angioplasty. Ichilov Magnesium Study Group.
    Roth A; Eshchar Y; Keren G; Sheps D; Kerbal S; Laniado S; Miller HI; Rubinstein A
    Am J Cardiol; 1994 Jun; 73(16):1154-8. PubMed ID: 8203331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of restenosis after coronary angioplasty. A study on demographic and metabolic variables.
    Johansen O; Abdelnoor M; Brekke M; Seljeflot I; Høstmark AT; Arnesen H
    Scand Cardiovasc J; 2001 Mar; 35(2):86-91. PubMed ID: 11405502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of restenosis by lovastatin after successful coronary angioplasty.
    Sahni R; Maniet AR; Voci G; Banka VS
    Am Heart J; 1991 Jun; 121(6 Pt 1):1600-8. PubMed ID: 2035374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient, lesion, and procedural variables as risk factors for luminal re-narrowing after successful coronary angioplasty: a quantitative analysis in 653 patients with 778 lesions. Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
    Hermans WR; Rensing BJ; Foley DP; Tijssen JG; Rutsch W; Emanuelsson H; Danchin N; Wijns W; Chappuis F; Serruys PW
    J Cardiovasc Pharmacol; 1993; 22 Suppl 4():S45-57. PubMed ID: 7523772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Normalization of lipid metabolism disturbances and clinical course after percutaneous coronary angioplasty: 6 month observation].
    Ochała A; Gabrylewicz B; Bartnik M; Garbocz P; Wycisk A; Lewicki A; Kaźmierski M; Tendera M
    Pol Arch Med Wewn; 2000 Dec; 104(6):833-41. PubMed ID: 11424662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can aggressive lipid lowering using low-density lipoprotein apheresis prevent restenosis after percutaneous transluminal coronary angioplasty in patients with normocholesterolemia?
    Yamashita K; Tasaki H; Tsuda Y; Himeno E; Nakashima Y
    Ther Apher; 1998 Aug; 2(3):210-7. PubMed ID: 10227772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial.
    Yokoi H; Daida H; Kuwabara Y; Nishikawa H; Takatsu F; Tomihara H; Nakata Y; Kutsumi Y; Ohshima S; Nishiyama S; Seki A; Kato K; Nishimura S; Kanoh T; Yamaguchi H
    J Am Coll Cardiol; 1997 Oct; 30(4):855-62. PubMed ID: 9316509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
    Gershlick AH; Spriggins D; Davies SW; Syndercombe Court YD; Timmins J; Timmis AD; Rothman MT; Layton C; Balcon R
    Br Heart J; 1994 Jan; 71(1):7-15. PubMed ID: 8297699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of continued smoking and some biological risk factors on restenosis after percutaneous transluminal coronary angioplasty.
    Kotamäki M; Laustiola K; Syvänne M; Heikkilä J
    J Intern Med; 1996 Nov; 240(5):293-301. PubMed ID: 8946812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.